150 related articles for article (PubMed ID: 25191397)
1. Short Term Effects of Tiotropium on COPD Patients Treated with Long Acting Bronchodilators.
Nicolini A
Tanaffos; 2012; 11(1):26-31. PubMed ID: 25191397
[TBL] [Abstract][Full Text] [Related]
2. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
3. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
Bateman ED; van Dyk M; Sagriotis A
Pulm Pharmacol Ther; 2008; 21(1):20-5. PubMed ID: 17118684
[TBL] [Abstract][Full Text] [Related]
4. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
Baloira Villar A; Vilariño Pombo C
Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
[TBL] [Abstract][Full Text] [Related]
5. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
[TBL] [Abstract][Full Text] [Related]
6. An acute bronchodilator test with tiotropium or salmeterol does not allow a subdivision of patients according to responses.
Matera MG; Sanduzzi A; Ponticiello A; Vatrella A; Salzillo A; Cazzola M
Respiration; 2005; 72(5):466-70. PubMed ID: 16210884
[TBL] [Abstract][Full Text] [Related]
7. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
[TBL] [Abstract][Full Text] [Related]
10. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
11. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Chong J; Karner C; Poole P
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009157. PubMed ID: 22972134
[TBL] [Abstract][Full Text] [Related]
12. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
[TBL] [Abstract][Full Text] [Related]
13. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
14. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Brusasco V; Hodder R; Miravitlles M; Korducki L; Towse L; Kesten S
Thorax; 2003 May; 58(5):399-404. PubMed ID: 12728159
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.
Ambrosino N; Foglio K; Balzano G; Paggiaro PL; Lessi P; Kesten S;
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):771-80. PubMed ID: 19281092
[TBL] [Abstract][Full Text] [Related]
16. The functional impact of adding salmeterol and tiotropium in patients with stable COPD.
Cazzola M; Centanni S; Santus P; Verga M; Mondoni M; di Marco F; Matera MG
Respir Med; 2004 Dec; 98(12):1214-21. PubMed ID: 15588043
[TBL] [Abstract][Full Text] [Related]
17. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.
Donohue JF; van Noord JA; Bateman ED; Langley SJ; Lee A; Witek TJ; Kesten S; Towse L
Chest; 2002 Jul; 122(1):47-55. PubMed ID: 12114338
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
19. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.
Wedzicha JA; Calverley PM; Seemungal TA; Hagan G; Ansari Z; Stockley RA;
Am J Respir Crit Care Med; 2008 Jan; 177(1):19-26. PubMed ID: 17916806
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
